Literature DB >> 26495954

Quantitative evaluation of headache severity before and after endoscopic transsphenoidal surgery for pituitary adenoma.

Amparo Wolf1, Sandy Goncalves1, Fateme Salehi2, Jeff Bird2, Paul Cooper3, Stan Van Uum4, Donald H Lee2, Brian W Rotenberg5, Neil Duggal1.   

Abstract

OBJECT The relationship between headaches, pituitary adenomas, and surgical treatment of pituitary adenomas remains unclear. The authors assessed the severity and predictors of self-reported headaches in patients referred for surgery of pituitary adenomas and evaluated the impact of endoscopic transsphenoidal surgery on headache severity and quality of life (QOL). METHODS In this prospective study, 79 patients with pituitary adenomas underwent endoscopic transsphenoidal resection and completed the Headache Impact Test (HIT-6) and the 36-Item Short Form Health Survey (SF-36) QOL questionnaire preoperatively and at 6 weeks and 6 months postoperatively. RESULTS Preoperatively, 49.4% of patients had mild headache severity, 13.9% had moderate severity, 13.9% had substantial severity, and 22.8% had intense severity. Younger age and hormone-producing tumors predisposed greater headache severity, while tumor volume, suprasellar extension, chiasmal compression, and cavernous sinus invasion of the pituitary tumors did not. Preoperative headache severity was found to be significantly associated with reduced scores across all SF-36 QOL dimensions and most significantly associated with mental health. By 6 months postoperatively, headache severity was reduced in a significant proportion of patients. Of the 40 patients with headaches causing an impact on daily living (moderate, substantial, or intense headache), 70% had improvement of at least 1 category on HIT-6 by 6 months postoperatively, while headache worsened in 7.6% of patients. The best predictors of headache response to surgery included younger age, poor preoperative SF-36 mental health score, and hormone-producing microadenoma. CONCLUSIONS The results of this study confirm that surgery can significantly improve headaches in patients with pituitary adenomas by 6 months postoperatively, particularly in younger patients whose preoperative QOL is impacted. A larger multicenter study is underway to evaluate the long-term effect of surgery on headaches in this patient group.

Entities:  

Keywords:  BP = bodily pain; GH = general health perceptions; HIT-6 = Headache Impact Test; MH = mental health; PF = physical function; QOL = quality of life; RE = role-emotional; RP = role-physical; SF = social functioning; SF-36 = 36-Item Short Form Health Survey; VT = vitality; endoscopic transsphenoidal surgery; headache; pituitary adenoma; pituitary surgery; quality of life

Mesh:

Year:  2015        PMID: 26495954     DOI: 10.3171/2015.5.JNS1576

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

1.  Relationship between postoperative volume of macroadenomas and clinical outcome after endoscopic trans-sphenoidal resection.

Authors:  Valeria Onofrj; Carina Vallejo; Paulo Puac; Carlos Zamora; Mauricio Castillo
Journal:  Neuroradiol J       Date:  2018-08-09

Review 2.  Headaches in Patients with Pituitary Tumors: a Clinical Conundrum.

Authors:  Laura E Donovan; Mary R Welch
Journal:  Curr Pain Headache Rep       Date:  2018-07-04

3.  Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study.

Authors:  Wouter R van Furth; Amir H Zamanipoor Najafabadi; Merel van der Meulen; Marco J T Verstegen; Daniel J Lobatto; Maarten C Kleijwegt; Alberto M Pereira; Nienke R Biermasz
Journal:  Pituitary       Date:  2022-01-10       Impact factor: 4.107

4.  Headache Before and After Endoscopic Transsphenoidal Pituitary Tumor Surgery: A Prospective Study.

Authors:  Agnes Andersson; Tobias Hallén; Daniel S Olsson; Dan Farahmand; Ann-Charlotte Olofsson; Eva Jakobsson Ung; Sofie Jakobsson; Henrik Bergquist; Gudmundur Johannsson; Oskar Ragnarsson; Thomas Skoglund
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-29

Review 5.  Clinical Presentation and Management of Headache in Pituitary Tumors.

Authors:  Himanshu Suri; Carrie Dougherty
Journal:  Curr Pain Headache Rep       Date:  2018-06-15

6.  Pituitary incidentalomas in paediatric age are different from those described in adulthood.

Authors:  Pedro Souteiro; Rúben Maia; Rita Santos-Silva; Rita Figueiredo; Carla Costa; Sandra Belo; Cíntia Castro-Correia; Davide Carvalho; Manuel Fontoura
Journal:  Pituitary       Date:  2019-04       Impact factor: 4.107

7.  Quality of Life and Sleep in Patients with Pituitary Adenoma in Relation to Tumor Type and Compression of the Optic Chiasm.

Authors:  Karol Piotr Sagan; Elżbieta Andrysiak-Mamos; Ernest Tyburski; Leszek Michał Sagan; Anhelli Syrenicz
Journal:  J Clin Med       Date:  2021-04-26       Impact factor: 4.241

8.  Neurosurgery concepts: Key perspectives on endoscopic versus microscopic resection for pituitary adenomas, surgical decision-making in tuberculum sellae meningiomas, optic nerve mobilization during resection of craniopharyngiomas, and evaluation of headache and quality of life after endoscopic transphenoidal surgery for pituitary adenomas.

Authors:  Anand V Germanwala; Ryan Hofler; Carlito Lagman; Lawrance K Chung; Alexander A Khalessi; Gabriel Zada; Zachary A Smith; Nader S Dahdaleh; Angela M Bohnen; Jin M Cho; Chaim B Colen; Edward Duckworth; Peter Kan; Sandi Lam; Chae-Yong Kim; Gordon Li; Michael Lim; Jonathan H Sherman; Vincent Y Wang; Isaac Yang
Journal:  Surg Neurol Int       Date:  2017-04-05

Review 9.  How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review.

Authors:  Cornelie D Andela; Daniel J Lobatto; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

10.  A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses.

Authors:  Nadine M Vaninetti; David B Clarke; Deborah A Zwicker; Churn-Ern Yip; Barna Tugwell; Steve Doucette; Chris Theriault; Khaled Aldahmani; Syed Ali Imran
Journal:  Endocr Connect       Date:  2018-04-30       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.